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Abstract
Alzheimer disease (AD) is an age-related disorder. Aging and female gender are two important risk factors associated with
sporadic AD. However, the mechanism by which aging and gender contribute to the pathogenesis of sporadic AD is
unclear. It is well known that genetic mutations in c-secretase result in rare forms of early onset AD due to the aberrant
production of Ab42 peptides, which are the major constituents of senile plaques. However, the effect of age and gender on
c-secretase has not been fully investigated. Here, using normal wild-type mice, we show mouse brain c-secretase exhibits
gender- and age-dependent activity. Both male and female mice exhibit increased Ab42:Ab40 ratios in aged brain, which
mimics the effect of familial mutations of Presenilin-1, Presenlin-2, and the amyloid precursor protein on Ab production.
Additionally, female mice exhibit much higher c-secretase activity in aged brain compared to male mice. Furthermore, both
male and female mice exhibit a steady decline in Notch1 c-secretase activity with aging. Using a small molecule affinity
probe we demonstrate that male mice have less active c-secretase complexes than female mice, which may account for the
gender-associated differences in activity in aged brain. These findings demonstrate that aging can affect c-secretase activity
and specificity, suggesting a role for c-secretase in sporadic AD. Furthermore, the increased APP c-secretase activity seen in
aged females may contribute to the increased incidence of sporadic AD in women and the aggressive Ab plaque pathology
seen in female mouse models of AD. In addition, deceased Notch c-secretase activity may also contribute to
neurodegeneration. Therefore, this study implicates altered c-secretase activity and specificity as a possible mechanism of
sporadic AD during aging.
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Introduction
Alzheimer disease (AD) is a progressive and fatal neurodegen-
erative disease that is postulated to result from aggregation of toxic
b-amyloid peptides (Ab) [1,2]. The vast majority of AD is sporadic
in nature and has no known genetic basis [3]. Age is the most
common risk factor associated with sporadic AD and the incidence
rates of AD across all ethnicities increase exponentially with age,
reaching 25 per 1,000 persons by age 85 [4]. Interestingly, gender
is also an established risk factor as women have been shown to
have a higher prevalence and risk for AD [5–10]. This apparent
gender bias has also been recapitulated in multiple mouse models
of AD as female mice exhibit more aggressive senile plaque
pathology compared to male mice [11–15]. However, the
molecular basis underlying this gender bias has not been fully
resolved.
Overproduction and impaired clearance of Ab can both
contribute to increased plaque formation. Ab peptides are
produced by the sequential processing of the amyloid precursor
protein (APP) by two proteases, b-secretase (BACE1) and c-
secretase [2]. Initial BACE1 processing of APP is required for
subsequent c-secretase mediated production of the Ab40 and
Ab42 peptides that are the major components of amyloid plaques.
APP can also be processed by a-secretase within in the Ab domain
and this cleavage precludes the formation of pathogenic Ab
peptides [16]. Numerous enzymes have been implicated in the
degradation of Ab peptides in the brain, including neprilysin,
insulin-degrading enzyme, as well as endothelin-converting
enzyme 1 and 2 [17]. The role of Ab generating and Ab
degrading enzymes in aging and sporadic AD has begun to be
investigated. Decreased neprilysin and insulin-degrading enzyme
activity and expression have been associated with aging and
increased activity of specific endothelin-converting enzyme 1
isoforms has been suggested to be protective against AD [18–20].
Elevated BACE1 activity has been found in both aged and AD
brains and is associated with increased Ab deposition [21,22].
Reduced a-secretase activity in AD brain and reduced expression
in the cerebral spinal fluid of AD patients has been reported
[23,24]. It is well established that mutations to presenilin (PS), the
catalytic subunit of c-secretase, are a causative factor in rare forms
of hereditary early onset AD and result in an increased
Ab42:Ab40 ratio [3]. However, the role of c-secretase activity in
PLoS ONE | www.plosone.org 1 April 2009 | Volume 4 | Issue 4 | e5088normal aging brain and sporadic AD has not been thoroughly
investigated.
To determine the effect of gender and aging on in vitro c-
secretase, we examined its activity in C57BL/6 mouse brain from
1–24 month old mice. We found that both aging and gender
significantly affect c-secretase activity and specificity; male mice
exhibited a sharp decline in brain APP c-secretase activity with
aging whereas female mice did not. Both male and female mice
exhibited an increased Ab42:Ab40 ratio in aged brain, indicating
altered c-secretase specificity during aging. The increased
Ab42:Ab40 ratio we detected in aged mouse brain is reminiscent
of the increased Ab42:Ab40 ratios seen in familial early onset AD
and can also be correlated with the Ab mediated plaque pathology
in AD patients. Additionally, age was found to have a significant
effect on Notch1 c-secretase activity with both male and female
mice having greatly reduced activity in aged brain suggesting
altered substrate processing abilities with age. Therefore, our
findings suggest a role for altered c-secretase activity and
specificity in aging and add to our understanding of the potential
aberrant Ab generating processes which play a role in the
pathogenesis of sporadic AD and neurodegeneration.
Results
c-Secretase activity exhibits age- and sex-dependent
activity for APP and Notch 1 processing
To determine if there was any age or gender influence on c-
secretase activity, we directly compared c-secretase activity
between male and female brains at varying ages. Total whole
brain membrane fractions were isolated from male and female
C57BL/6 mice at 1, 12, 18, and 24 months of age and in vitro c-
secretase activity was measured using a recombinant APP
substrate. Ab40 and Ab42 were detected using G2-10 and G2-
11 antibodies, respectively. Interestingly, male and female mice
exhibited distinct activity profiles for both Ab40 and Ab42
production during aging (Figure 1A, left and middle panel,
respectively). Male mice exhibited consistent Ab40 production at
1, 12, and 18 months with 7500–8200 units/min/mg. However, at
24 months, male mice had approximately a two fold reduction in
Ab40 c-secretase activity compared to 1 month, producing only
4500 units/min/mg (Figure 1A, left panel, open circles,
p,0.00002). On the contrary, Ab42 production in male mice
was maintained at 70–95 units/min/mg during aging (Figure 1A,
middle panel, open circles).
Although female mice had similar Ab40 activity as males at 1
month, there was a transient 15–25% decline in Ab40 activity in
female mice at 12 and 18 months but by 24 months Ab40 activity
had returned to the 1 month baseline levels (Figure 1A, left panel,
filled circles). Female mice therefore exhibited 65% more Ab40
production compared to male mice at 24 months of age
(p,0.00008). Similar to Ab40 activity, there was a transient
decline in Ab42 production in female mice at 12 months but Ab42
activity levels increased at 18 and 24 months resulting in a 30%
increase in Ab42 activity at 24 months compared to 1 month
(Figure 1A, middle panel, filled circles, p,0.004). Compared to
male mice, female mice had 68% more Ab42 activity at 24 months
of age (p,0.001). Both female and male mice had a similar
increase in the Ab42:Ab40 ratio with aging, with a 40% and 60%
increase at 24 months compared to 1 month, respectively
(Figure 1A, right panel, p,0.01 female, p,0.057 male).
We next examined c-secretase sensitivity to two structurally
distinct inhibitors, L685,458 (L458) and Compound E. Ab40 in
vitro c-secretase activity was measured in the presence of increasing
concentrations of either L458 (Figure 1B, left panels) or
Compound E (Figure 1B, right panels). There was no difference
in efficacy or potency of either L458 or Compound E in either
females or males. Furthermore, there was no age related
differences in efficacy or potency for either compound.
We then examined BACE1 activity in young (1 month) and
aged (24 month) brain. Membrane isolated from mouse brain was
incubated with an APP peptide substrate containing the Swedish
mutation in the presence or absence of StatineV, a potent BACE1
inhibitor. Background was defined as the activity remaining in the
presence of StatineV. At 1 month of age, female mice had about
15% more BACE1 activity than male mice (Figure 2, p,0.009).
However, we found that both male and female mice had a 20–
30% increase in BACE activity at 24 months compared to 1
month (Figure 2, p,0.0005). Significantly, there was no gender
associated difference in BACE1 activity in aged brain (Figure 2, 24
months, p=0.4).
In addition to APP, c-secretase is also known to process Notch1.
Therefore, we wished to determine if there were any age or gender
dependent changes in c-secretase activity for Notch1 processing as
we saw with APP processing. Total whole brain membrane
fractions from 1, 12, 18, and 24 month old C57BL/6 mice were
assayed for in vitro Notch1 c-secretase activity using a recombinant
Notch1 substrate. Both male and female mice had similar levels of
Notch1 activity at 1 month of age, producing about 1000 NICD1
units/min/mg (Figure 3, p=0.1). However, Notch1 c-secretase
activity declined sharply with age; both male and female aged mice
(24 month) exhibited only about 50% of the Notch1 activity as
compared to young mice (1 month) (Figure 3, Female p,0.0002,
Male p,0.001). While female mice had higher Notch1 c-secretase
activity at 12 and 18 months compared to males (p,0.006 and
p,0.01, respectively), there was no gender dependent differences
in Notch1 activity at 24 months (p=0.3).
Both male and female aged brains have reduced levels of
total Nct and PS1
Because there was a significant difference in c-secretase activity
between male and female brain at 24 months, we determined if
there were any changes in the protein levels of the core subunits of
c-secretase which could account for the distinct sex specific activity
profiles. Equal amounts of total membrane were resolved by SDS-
PAGE and western blotted for the core c-secretase subunits:
nicastrin (Nct), presenilin (PS), Aph1aL, and Pen2. There was a
reduction in Nct and PS1 levels at 24 months in male and female
mice (Figure 4A, panels 1–3) but no change in expression of PS2-
CTF, Aph1aL, and Pen2 with aging (Figure 4A, panels 4–6). The
area under the curve (AUC) was measured from multiple western
blots and normalized as a percentage of 1 month female as a
means of quantification. There was a significant 50–60%
reduction in the levels of Nct, PS1-NTF, and PS1-CTF for both
female and male mice at 24 months (Figure 4B, p,0.03). There
were no significant changes in the protein levels of PS2-CTF,
Aph1aL, and Pen2 (data not shown).
Male, but not female, mice show reduced photolabeling
of presenilin in aged brain
We have previously shown that c-secretase activity does not
always correlate with total expressed subunit levels [25]. In
addition, only a fraction of expressed subunits, as measured by
western blotting, are actually incorporated into enzymatically
active complexes [26,27]. Therefore, western blotting alone is not
adequate for exploring the relationship between activity and
expression of active complexes. We previously developed and
characterized a panel of small molecule affinity probes based on
c-Secretase in Aged Mice
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active c-secretase complexes [25]. We designed an improved
version, designated compound 5, with a longer and more
hydrophilic biotin linker for capture of endogenous active c-
secretase and a photoreactive benzophenone group that can be
used to covalently photolabel the active site (Figure 5A).
Compound 5 can inhibit c-secretase isolated from HeLa
membrane with an IC50 of ,4 nM (data not shown). We used
compound 5 to photolabel PS1-NTF and PS1-CTF, the catalytic
core, of c-secretase. Total brain membrane was incubated with
compound 5 in the presence or absence of excess L458 and
irradiated to covalently crosslink the probe with the active site of c-
secretase. The labeled components were separated by SDS-PAGE
and western blotted for PS1-NTF and PS1-CTF. The catalytic
core was clearly photolabeled by compound 5 and this labeling
was completely blocked by inclusion of excess L458, indicating
specific labeling of the target protein. Male mice exhibited a
reduction in photolabeling of both PS1-NTF and PS1-CTF at 24
months (Figure 5A, M=male). However, female mice did not
display the same decrease in photolabeling at 24 months as male
mice (Figure 5A, F=female). Quantification of the relative AUC
of multiple photolabeling experiments revealed male mice had
approximately a 45% reduction in PS1-CTF and PS1-NTF
photolabeling at 24 months compared to 1 month (Figure 5B,
open circles) whereas female mice had no significant changes in
the amount of labeled PS1 (Figure 5B, filled circles). At 24 months
male mice had 60% less photolabeled PS compared to female
mice, indicating that male mice had less active c-secretase
complexes than female mice in aged brain or an altered
conformation of the active site (Figure 5B, p,0.016).
Discussion
Aging and gender are risk factors that are clearly associated with
sporadic AD. However, whether or not these risk factors directly
affect c-secretase production of Ab is not known. Multiple mouse
models have been used to recapitulate Ab pathology and have
proved to be useful tools in understanding the pathogenesis of AD
[28]. We therefore utilized wild type mouse brain to examine the
effect of age and gender on the activity and specificity of c-
Figure 1. Age- and gender-specific APP c-secretase activity in C57BL/6 mouse brain. (A) Male mice exhibit reduced c-secretase production
of Ab40 and Ab42 peptides in aged brain compared to females but both males and females exhibit increased Ab42:Ab40 ratios. In vitro c-secretase
activity for Ab40 (left) and Ab42 (middle) production from total mouse brain was measured using a recombinant APP substrate. Background was
defined as activity remaining in the presence of 1 mM Compound E. Values represent background subtracted ECL units/min/mg membrane
(average6s.e.m., n=16). The Ab42:Ab40 ratio was calculated (right) (average6s.e.m., n=8). (B) There is no effect of age or gender on sensitivity to
distinct c-secretase inhibitors. In vitro Ab40 c-secretase activity from total female and male mouse brain was measured using a recombinant APP
substrate in the presence of increasing concentrations of L458 (left) or Compound E (right). The compound structures are indicated. Background was
defined as activity remaining in the presence of 1 uM compound. Activity is plotted as a percentage of background subtracted maximal activity (%
Max). Curves were generated using a sigmodial three parameter logistic fit in SigmaPlot8.0 (average6s.e.m, n=4).
doi:10.1371/journal.pone.0005088.g001
c-Secretase in Aged Mice
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Ab42:Ab40 ratio in aging mice indicating that c-secretase
specificity for Ab40 and Ab42 processing varies with age. Recent
studies suggest that the ratio of Ab42:Ab40, rather than the total
levels of Ab, is better correlated with AD pathology and subtle
changes to the Ab42:Ab40 ratio promotes Ab aggregation and
toxicity [29–31]. Therefore, our data which demonstrates
increased Ab42:Ab40 ratios in aged mice may account for, in
part, the increased incidence of sporadic AD seen during aging
(Figure 6, (a)). In addition, we found that aging also leads to an
elevation of BACE1 activity, which is consistent to previous
reports showing increased BACE1 activity in both aged and AD
brains and further supports a role for aberrant APP processing in
sporadic AD (Figure 6, (b)) [21,22]. Second, we have shown that
aged female mouse brain has 65% more in vitro c-secretase activity
at 24 months compared to male mice. Although female and male
mice both have increased Ab42:Ab40 ratios at 24 months, the fact
that female mice have elevated c-secretase activity suggests that
their overall plaque burden would be increased compared to male
mice due to increased APP processing (Figure 6, (c)). Furthermore,
we demonstrated that there were no gender differences in BACE1
activity in aged brain, indicating that the increased in vitro c-
secretase activity in female mice at 24 months would likely be
translated into increased Ab production in vivo. These data
establish a potential role for elevated APP c-secretase activity in
aged females as an additional causative factor in the increased
prevalence of AD in women and increased plaque burden seen in
female mouse models of AD.
Photolabeling of PS1 suggests that the reduction in c-secretase
activity seen in aged males is due to either the reduced formation
of active complexes or alterations to the active site architecture
which reduce APP processing. However, the precise mechanism
by which high levels of c-secretase activity are maintained in aged
female mouse brain remains unknown.
The decline in estrogen during menopause has been suggested
to be a causative factor in the increased prevalence of AD in
women. Early reports of hormone replacement therapy suggested
a protective role of estrogen in the pathogenesis of AD [32–34].
However, more recent reports have found that estrogen
replacement fails to protect against the development or progres-
sion of AD and in some cases worsens disease progression [35–38].
Estrogen has been shown to reduce APP processing in animal and
cell model systems via a variety of mechanisms including increased
trafficking of APP out of the trans-Golgi network and increased a-
secretase mediated APP cleavage which would lead to a reduction
in available APP substrate for c-secretase processing [39–41].
Estrogen deficiencies have been associated with increased Ab
deposition via increased BACE1 activity and decreased neprilysin/
insulin-degrading enzyme activity, both of which were detected as
gender specific biochemical markers associated with aggressive
plaque deposition in mouse models of AD [12,13,42]. It is known
that changes in estrogen levels can influence the lipid and
lipoprotein profiles in women [43–46]. Furthermore, it is known
that changes to the lipid microenvironment can have a large
impact on c-secretase activity [47–49]. A cellular model of aging in
normal human fibroblasts demonstrated a downregulation of c-
secretase activity due to disruptions in the lipid raft microenvi-
ronment [50]. Therefore, the potential effect of aging and estrogen
deficiencies on the lipid environment of brain and c-secretase
activity warrants investigation and may provide insight into the
gender specific c-secretase activity differences in aged brain we
observed.
Interestingly, the gender dependant effects on c-secretase
activity appear to be specific for APP processing as both male
and female mice exhibited a decline in Notch1 c-secretase activity
during aging and exhibit no gender associated differences at 24
months. Aged brain c-secretase complexes, therefore, have gender
Figure 2. Analysis of BACE1 activity in young and aged C57BL/
6 mouse brains. Both male and female mice show an increase in
BACE1 activity in aged brain. 10 mg brain membrane was assayed for
BACE1 activity using a 12-mer FRET based substrate. Background was
defined as activity remaining in the presence of 5–10 mM StatineVal.
Values represent background subtracted fluorescent intensity (aver-
age6s.e.m., n=14).
doi:10.1371/journal.pone.0005088.g002
Figure 3. Age- and gender-specific Notch1 c-secretase activity
in C57BL/6 mouse brain. Both male and female mice exhibit an age-
dependent reduction in Notch1 c-secretase activity. In vitro c-secretase
activity for NICD1 production from total mouse brain was measured
using a recombinant Notch1 substrate. Background was defined as
activity remaining in the presence of 1 mM Compound E. Values
represent background subtracted ECL units/min/mg membrane (average
6s.e.m., n=16).
doi:10.1371/journal.pone.0005088.g003
c-Secretase in Aged Mice
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strongly favoring APP over Notch1 as a substrate and male brain
showing no significant age related changes in its relative substrate
preference. These data suggest that discrete c-secretase complexes
exist in brain which exhibit unique activity profiles, substrate
processing abilities and regulation.
Notch signaling pathways are critical for cell fate decisions
during development and direct proliferative, differentiation, and
apoptotic responses [51]. In addition to its pivotal role in
neurogensis during embryonic development, Notch signaling is
involved in many aspects of central nervous system development in
the postnatal and adult brain including the maintenance of
neuronal stem cells, neuronal proliferation, and dendritic arbor-
ization; this Notch signaling is dependent on PS expression and
function [52–55]. Importantly, it has been shown that a subset of
PS FAD mutations result in the loss of c-secretase mediated
Notch1 cleavage [56–58]. Furthermore, conditional loss of PS in
adult mouse brain leads to loss of synaptic plasticity, memory
impairments, and age-dependant neurodegeneration through the
loss of Notch activation of CRE-dependent gene expression [59].
Therefore, the age dependent reduction in Notch1 c-secretase
activity we detected in male and female brain may also contribute
to the severity of sporadic AD due to enhanced neurodegeneration
(Figure 6, (d)).
Figure 4. Western blot analysis of total protein levels of c-secretase subunits in C57BL/6 mouse brain. (A) Both female and male mice
have a reduction in the protein levels of Nct and PS1, but not PS2, Aph1aL or Pen2, in aged brain. Equal amounts of total brain membrane was
separated on SDS-PAGE and western blotted for the indicated subunits of c-secretase. Representative blots shown. F=Female, M=Male. (B) There is
a 50–60% reduction in total protein levels of Nct (left) and PS (middle and right) in 24 month male (open circles) and female mice (filled circles).
Quantification of the relative band intensities of multiple western blots was calculated by measuring the area under the curve (AUC) using the gel
analysis function of ImageJ software. Blots were internally normalized to the relative band intensity of 1 month female. Values represent percentage
of 1 month (%1 mo) female AUC. (average6s.e.m. n=4).
doi:10.1371/journal.pone.0005088.g004
c-Secretase in Aged Mice
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activity during aging in the development of sporadic AD and
neurodegeneration; aged mice exhibit altered specificity for Ab40
and Ab42 production and decreased Notch1 processing, both of
which are reminiscent of certain PS FAD mutations that result in
the development of early onset AD. Furthermore, our demonstra-
tion that female mice have much greater c-secretase activity in
aged brain compared to males offers an additional model to
explain the increased prevalence of AD in women and aggressive
plaque pathology seen in female mouse models. Increased c-
secretase activity, along with altered Ab42 and Ab40 specificity, in
aged brain, would potentially exacerbate the plaque load in
females. This model would work in concert with previously
demonstrated increases in BACE1 activity and reductions in
neprilysin activity in female mouse models of AD. Additionally,
loss of Notch1 c-secretase activity in aged mouse brain may also
augment the pathological consequences of increased Ab42:Ab40
ratios and increased Ab production by increasing neurodegener-
Figure 5. c-Secretase active site photoloabeling of C57BL/6 mouse brain. (A) Aged male mice have reduced photolabeling of PS1 compared
to female mice at 24 months. The structure of compound 5 is indicated. The biotin moiety is marked with a dashed box, the photoreactive
benzophenone is marked with a dashed circle, and the linear distance between the biotin moiety and the L458 backbone is 57A ˚ as determined in
ChemDraw. Equal amounts of total membrane were covalently photolabeled with compound 5 in the presence (L458, 1 month female shown as
representative) or absence (DMSO) of non-biotinylated L458. Following denaturation with RIPA buffer, the labeled proteins were captured with
streptavidin agarose, separated by SDS-PAGE and western blotted for PS1-NTF (upper panel) and PS1-CTF (lower panel). Representative blot shown.
F=Female. M=Male. (B) Male mice have a 60% reduction in PS photolabeling at 24 months compared to females. Quantification of the relative band
intensities of multiple photolabeling experiments was calculated by measuring the area under the curve (AUC) using the gel analysis function of
ImageJ software. Blots were internally normalized to the relative band intensity of 1 month female. Values represent percentage of 1 month (%1 mo)
female AUC. (average6s.e.m., n=4).
doi:10.1371/journal.pone.0005088.g005
c-Secretase in Aged Mice
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dependent gene expression. Therefore, our data help to clarify
the roles of aging and female gender as risk factors for sporadic AD
and advance our understanding of aberrant c-secretase activity as
a potential mechanism underlying the pathogenesis of sporadic
AD.
Materials and Methods
Chemical compounds and antibodies
Synthesis of L685,458 and Compound E were previously
described [60,61]. Compound 5 was synthesized by using the same
procedure as previously described [62]. Nct and SM320 (activated
Notch1) antibodies were generated in our laboratory. Antibodies
against PS1-NTF and Pen2 were a kind gift of Dr. Min-tain Lai
(Merck Research Labratories) and Dr. Jan Na ¨slund (Karolinka
Institutet), respectively. The remaining antibodies were commer-
cially purchased: PS1-CTF (Chemicon, MAB5232), PS2-CTF
(Calbiochem, PC235), and Aph1aL (Zymed, 38–3600). H-Glu-
Val-Asn-[(2R,4S,5S)-5-amino-4-hydroxy-2,7-dimethyl-octanoyl]-
Ala-Glu-Phe-OH (StatineV) was purchased from Bachem.
Membrane preparation
C57BL/6 mouse whole brain (male and female at 1, 12, 18, and
24 months of age) was obtained flash frozen from the NIA/NIH
aged rodent tissue bank (Bethesda, MD) or special ordered from
Taconic (Hudson, NY). Animals were tumor free with no gross
pathologies or illnesses. Total membrane was isolated from two
brains for each age and gender (Table S1). Briefly, 2 whole brains
were thawed on ice, resuspended together in ice cold Buffer A
(50 mM MES, pH 6.0, 150 mM KCl, 5 mM CaCl2,5 m M
MgCl2, and protease inhibitors), and Dounce homogenized.
Nuclear debris was cleared by low speed centrifugation and the
resulting supernant was ultracentrifuged 100,0006g for 1 h at
4uC. The resulting pellet, representing the total membrane
fraction, was resuspended in Buffer A and Dounce homogenized.
Protein concentration was measured with the DC Protein Assay
Kit per manufacturer’s instructions (Bio-Rad) and was approxi-
mately 5 mg/mL.
In Vitro c-Secretase Activity Assay
c-Secretase activity was measured using the previously de-
scribed electrochemiluminescence method [63,64]. Brain mem-
brane (4 mg) was incubated with Buffer B (50 mM PIPES pH 7.0,
150 mM KCl, 5 mM CaCl2, 5 mM MgCl2 and protease
inhibitors) with 0.25% CHAPSO (v/v), 1 mM recombinant
biotinylated APP substrate or 0.2 mM recombinant biotinylated
Notch1 substrate, and 0.1% bovine serum albumin (v/v) in the
presence of 1 mM Compound E or DMSO for 2.5 h at 37uC. The
reaction mixture was incubated with ruthenylated G2-10 or G2-11
to detect Ab40 and Ab42 peptides, respectively, or SM320 in
conjunction with ruthenylated anti-rabbit to detect Notch1
intracellular domain (NICD1) in Buffer C (16phosphate-buffered
saline and 0.5% Tween 20 (v/v)) for 2 h at room temperature.
Immunocomplexes were captured with magnetic strepavidin
beads (Dynal) and Ab40, Ab42, and NICD1 production was
measured by electrochemiluminescence. Activity is expressed as
relative light units/min/g membrane. Brain c-secretase activity
was measured from two independent membrane preparations
(n=4 animals total). Data points from four independent assays (2
assays for each individual membrane preparation) were averaged.
P values were determined using a student t test in SigmaPlot8.0.
In Vitro BACE1 Activity Assay
BACE1 activity was measured using a 12-mer FRET based
substrate (TAMRA-Glu-Glu-Ile-Ser-Glu-Val-Asn-Leu-Asp-Ala-
Glu-Phe-QSY 7 amide). 10 mg membrane was incubated in
BACE1 Assay Buffer (500 mM Sodium Acetate pH 4.5, 150 mM
NaCl, and 0.1 mg/mL BSA) with 0.2% CHAPS (v/v) and 5 mM
substrate in the presence or absence of 5–10 mM StatineV for 2 h
at 37uC in the dark. BACE1 cleavage of the substrate was detected
by excitation of the fluorophore at 530 nm and emission was
Figure 6. Model of potential age and gender dependent pathogenic pathways resulting in neurodegeneration. Pathologic Ab
production can be mediated by (a) altered c-secretase specificity resulting in increased Ab42:Ab40 ratios leading to increased pathogenic plaque
deposition (b) increased BACE1 activity which increases the levels of available APP substrate and therefore production of Ab peptides (c) increased
APP c-secretase activity which results in increased Ab production. In addition to pathogenic Ab pathways, loss of Notch1 signaling due to decreased
Notch1 c-secretase activity may also lead to a neurodegenerative state (d). The data presented here implicates aging in pathways (a), (b), and (d) in
the development of AD whereas (c) is an additional causative pathway implicated in the pathogenesis of neurodegeneration in females.
doi:10.1371/journal.pone.0005088.g006
c-Secretase in Aged Mice
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(Envision, PerkinElmer). Activity is expressed as fluorescent
intensity at 580 nm. Activity was measured in two independent
membrane preparations (n=4 animals total). Data points from
two independent assays were averaged. P values were determined
using a student t test in SigmaPlot8.0.
Western blotting and photolabeling
For western blotting, 20 mg total membrane was prepared with
46 reducing Lammeli sample buffer, separated by SDS-PAGE
and transferred to PVDF membrane. Following blocking, the
following antibodies were used for western blotting: Nct (1:1000),
PS1-NTF (1:1000), PS1-CTF (1:1000), PS2-CTF (1:1000),
Aph1aL (1:250), and Pen2 (1:500). Anti-mouse or anti-rabbit
horseradish peroxidase conjugated secondary antibodies were used
in concert with standard enhanced chemiluminescence detection
methods. For photolabeling, 800 mg total membrane was pre-
incubated with 2 mM non-biotinylated L458 or DMSO for 0.5 h
at 37uC in Buffer B supplemented with 0.25% CHAPSO (v/v).
Following pre-incubation, 20 nM compound 5 was added for 1 h
at 37uC. Covalent crosslinking was performed by photoactivation
of the benzophenone moiety at 350 nm for 0.75 h on ice. The
reaction was denatured with 16 RIPA (50 mM Tris pH 8.0,
150 mM NaCl, 0.1% SDS (w/v), 1% Nonidet P40 (v/v), and
0.5% deoxycholic acid (w/v)) for 1 h at room temperature. The
labeled complexes were captured with streptavidin agarose for
16 h at 4uC. The captured complexes were washed with 16RIPA,
eluted with 26reducing Lammeli sample buffer, and resolved by
SDS-PAGE. Western blotting was performed as described above.
In all cases, blots are representative of a minimum of three
independent experiments.
Supporting Information
Table S1
Found at: doi:10.1371/journal.pone.0005088.s001 (0.78 MB EPS)
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